Natural supplement trial offers hope for rare immune disorder lung damage
NCT ID NCT05593588
Summary
This study is testing whether a supplement called Fisetin can help treat lung scarring in people with common variable immunodeficiency (CVID), a rare immune system disorder. Twenty participants will receive either Fisetin or a placebo to see if it improves lung function, reduces lung damage on scans, and enhances quality of life. The goal is to find a new treatment option for this challenging complication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMMON VARIABLE IMMUNODEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.